Below are the most recently updated broker updates which include ratings and price targets for Apricus Biosciences, Inc (APRI).

12/09/2015 – Broker: Sterne Agee Rating: neutral downgrade

11/06/2015 – Broker: Roth Capital Rating: neutral New Target: 1.5 downgrade

08/13/2015 – Broker: Ascendiant Capital Markets Rating: buy New Target: 2.5 newcoverage

05/11/2015 – Broker: Zacks Rating: hold upgrade

02/23/2015 – Broker: Taglich Brothers Rating: speculative buy New Target: 5.8 newcoverage

10/28/2014 – Broker: Cantor Fitzgerald Rating: hold New Target: 1.5 reiteration

The average price target from the most recent broker reports is 2.83

The stock decreased -2.36% (-0.01) during the last days session, reaching 0.46 and roughly 332038 shares were bought or sold by traders.

View other investors thoughts on Apricus Biosciences, Inc with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.